MetaCap

4D Molecular Therapeutics (FDMT) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Surrozen (SRZN) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 115.6% versus a loss of 5.6%. Over five years, FDMT leads with a -53.6% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $576.8 million), about 1.0 times the size, while 4D Molecular Therapeutics is growing revenue faster (+230194.6% vs -67.4%).

4D Molecular Therapeutics converts more of its revenue into profit, with a net margin of -164.4% versus -6960.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FDMT-5.63%SRZN+115.61%
+168%+62%-43%
Nov 21, 20251 yearNov 20, 2026
FDMT-55.64%SRZN-79.38%
+53%-25%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FDMT versus SRZN key metrics
MetricFDMTSRZN
Share price$10.23$28.46
Market cap$576.76M$596.40M
1-day change-4.57%-7.21%
YTD return+36.40%+25.93%
1-year return-5.63%+115.61%
5-year return-53.61%-78.97%
EPS (TTM)$-2.70$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.21M$3.48M
Revenue growth (YoY)+230194.59%-67.37%
Net income (latest FY)$-140.11M$-242.03M
Operating margin-187.24%-1210.58%
Net margin-164.43%-6960.77%
52-week high$16.93$37.83
52-week low$6.96$12.79
Distance from 52-week high-39.57%-24.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+174.58%+123.12%
Average volume967.00K537.16K
Shares outstanding56.38M20.96M
Employees19644
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SRZN has outperformed FDMT by 121.2 percentage points over the past year.
  • 4D Molecular Therapeutics is more profitable, keeping -164.4 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
  • 4D Molecular Therapeutics grew revenue faster in its latest fiscal year (+230194.59% vs -67.37%).

About 4D Molecular Therapeutics

FDMT stock →

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

FDMT vs SRZN FAQ

Which is bigger, 4D Molecular Therapeutics or Surrozen?

Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $576.76M for 4D Molecular Therapeutics (FDMT).

Which stock has performed better over the past year, FDMT or SRZN?

SRZN returned +115.61% over the past 12 months, compared with -5.63% for FDMT (price return, excluding dividends). Past performance does not predict future results.

Are 4D Molecular Therapeutics and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons